Chronic HBV Infection Clinical Trial
Official title:
A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of EDP 514 in Viremic Chronic Hepatitis B Virus Infected Patients Not Currently on Treatment
Verified date | January 2022 |
Source | Enanta Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.
Status | Completed |
Enrollment | 25 |
Est. completion date | August 30, 2021 |
Est. primary completion date | August 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - An informed consent document signed and dated by the subject. - Healthy male and female subjects of any ethnic origin between the ages of 18 and 70 years, inclusive - HBV DNA levels: - For subjects who are HBeAg positive at Screening, a Screening HBV DNA level in serum/plasma that is =20,000 IU/ml, or - For subjects who are HBeAg negative at Screening, a Screening HBV DNA level in serum/plasma that is =2,000 IU/mL, and - For all subjects, no HBV DNA serum/plasma test values <1,000 IU/ml over the previous 12 months (using an approved test) - CHB subjects must not have been on prescribed anti-HBV treatment for at least 12 months prior to Screening Exclusion Criteria: - A documented prior diagnosis of cirrhosis - Pregnant or nursing females - Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV - Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Queen Mary Hospital | Hong Kong | |
Taiwan | Changhua Christian Hospital | Changhua | |
Taiwan | Chia-Yi Christian Hospital | Chiayi | |
Taiwan | E-Da Hospital/E-DA Cancer Hospital | Kaohsiung | |
Taiwan | Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Linkou Branch | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Enanta Pharmaceuticals | Pharmaceutical Research Associates |
Hong Kong, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety measured by adverse events | Up to 84 Days in HBV MAD Cohorts | ||
Secondary | Cmax of EDP-514 | Up to 28 Days in HBV MAD Cohorts | ||
Secondary | AUC of EDP-514 | Up to 28 Days in HBV MAD Cohorts | ||
Secondary | Change from baseline in HBV DNA Viral Load Assay | through Day 28 in HBV MAD Cohorts |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05019040 -
Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01943799 -
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
|
Phase 2 | |
Recruiting |
NCT05792761 -
A Study on Antiviral Treatment of Chronic Hepatitis B in Children
|
N/A | |
Completed |
NCT05468060 -
Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04008004 -
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
|
Phase 1 | |
Active, not recruiting |
NCT05734807 -
A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
|
Phase 2 | |
Completed |
NCT06029634 -
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
|
||
Completed |
NCT04147208 -
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
|
Phase 2 | |
Completed |
NCT03909191 -
Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
|
||
Completed |
NCT03664518 -
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
|
Phase 2 | |
Completed |
NCT05542979 -
A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection
|
Phase 1 | |
Active, not recruiting |
NCT03903796 -
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
|
Phase 3 | |
Completed |
NCT05851261 -
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects
|
Phase 1 |